Reaffirmed: Syros Pharmaceuticals (SYRS) Outperform Rating Reaffirmed by Wedbush; $13 Target in Place

March 14, 2018 - By Peter Erickson

 Reaffirmed: Syros Pharmaceuticals (SYRS) Outperform Rating Reaffirmed by Wedbush; $13 Target in Place

Syros Pharmaceuticals (SYRS) Rating Reaffirmed

The company has just set a target price of $13 on Syros Pharmaceuticals (SYRS) shares. This is 5.78 % from the last close price. In an analyst report issued to clients on Tuesday morning, Wedbush reconfirmed their Outperform rating on shares of SYRS.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Ratings Coverage

Among 7 analysts covering Syros Pharmace… (SYRS), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Syros Pharmace… has $30 highest and $1000 lowest target. $19.40’s average target is 57.85% above currents $12.29 stock price. Syros Pharmace… had 15 analyst reports since July 18, 2016 according to SRatingsIntel. On Thursday, August 10 the stock rating was downgraded by JMP Securities to “Market Perform”. The rating was initiated by Roth Capital with “Hold” on Monday, October 23. JMP Securities upgraded the shares of SYRS in report on Thursday, September 28 to “Market Outperform” rating. The firm has “Buy” rating given on Monday, June 19 by Oppenheimer. The stock of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) earned “Buy” rating by Oppenheimer on Friday, July 21. The stock of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) earned “Buy” rating by Oppenheimer on Monday, August 21. Oppenheimer maintained Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) rating on Wednesday, August 9. Oppenheimer has “Buy” rating and $2800 target. The stock of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) earned “Hold” rating by H.C. Wainwright on Monday, June 19. The firm has “Neutral” rating given on Monday, July 18 by H.C. Wainwright. The rating was maintained by Roth Capital with “Hold” on Wednesday, November 1.

The stock decreased 1.44% or $0.18 during the last trading session, reaching $12.29. About 200,834 shares traded. Syros Pharmaceuticals, Inc. (SYRS) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to report earnings on May, 21. They expect $-0.34 earnings per share, up 30.61 % or $0.15 from last year’s $-0.49 per share. After $-0.58 actual earnings per share reported by Syros Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -41.38 % EPS growth.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $395.59 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

More notable recent Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) news were published by: which released: “Free Research Reports on These Biotech Stocks — Seattle Genetics, Spectrum …” on February 27, 2018, also with their article: “Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 …” published on December 10, 2017, published: “Incyte and Syros Announce Global Target Discovery and Validation Collaboration …” on January 08, 2018. More interesting news about Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) were released by: and their article: “5 Keys To Understanding Syros Pharma’s ASH Presentation” published on December 11, 2017 as well as‘s news article titled: “Syros Announces Proposed Offering of Common Stock” with publication date: January 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.